Analysts say these 4 ASX blue chip shares are buys

If you’re wanting to bolster your portfolio with some ASX blue-chip shares, then read on!

That’s because listed below are four blue chips that have been named as buys by analysts. Here’s what you need to know about them:

Aristocrat Leisure Limited (ASX: ALL)

Aristocrat Leisure could be an ASX blue-chip share to buy. It is a gaming technology company with a portfolio of world-class businesses across pokie machines, digital and mobile games, and real money gaming.

The team at Morgans is very positive on Aristocrat and has an add rating and a $45 price target on its shares.

Cochlear Limited (ASX: COH)

Cochlear is another ASX blue-chip share that has been rated as a buy. It is a leading player in the development, manufacture, and distribution of cochlear implantable devices for the hearing impaired. Its products include the Nucleus System (cochlear implant) and Baha System (bone conduction).

Goldman Sachs likes the company due to its “stronger pricing power” and “more resilient/expanding market shares.” Its analysts have a buy rating and a $265 price target on its shares.

CSL Limited (ASX: CSL)

Morgans is also a fan of CSL and believes it could be an ASX blue-chip share to buy. In fact, the broker continues to describe the biotherapeutics giant as “a key portfolio holding.” In addition, its analysts believe its “shares [are] offering good value trading around its long-term forward multiple of ~30x.”

Morgans has an add rating and a $323 price target on its shares.

Qantas Airways Limited (ASX: QAN)

A final ASX blue-chip share that could be a buy is airline operator Qantas. Goldman Sachs is very positive on the company and believes its shares are undervalued. Its analysts note that “the current share price does not reflect the group’s improved earnings capacity.”

Goldman has a conviction buy rating and a $8.50 price target on its shares.